Is Halozyme Therapeutics, Inc. overvalued?

Halozyme Therapeutics, Inc. (HALO) looks undervalued — trading about 17% below its fair value.

Undervalued

Price

$100.27

Fair value

$117.77

Current P/E

21.7

Normal P/E

25.5

Market cap

$11.43B

Dividend yield

0.0%

Return on equity

544.3%

Sector

Healthcare

Fair value compares HALO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks